Inclusion Criteria:

- Patients must have signed an approved informed consent.

- must have histologically documented untreated gastric/GEJ carcinoma (clinical stage
T3 N0 or T4, or any T with N1-N3 M0)

- Patients with tumor tissue available for assessment of EGFR status by IHC.

- Patients with Performance Status 0-2.

- Patients, 18 years and older, must either be not of child bearing potential or have a
negative pregnancy test within 7 days of treatment. Patients are considered not of
child bearing potential if they are surgically sterile (they have undergone a
hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are
postmenopausal.

- Bone marrow function: absolute neutrophil count (ANC) at least 1,500/ul; platelets at
least 100,000/ul.

- Renal function: creatinine not greater than 1.5 x institutional upper limit of normal
(ULN).

- The PT and PTT should be within the range of normal values

- Hepatic function: bilirubin not greater than 1.5 x ULN; AST not greater than 2.5 x
ULN.

Exclusion Criteria:

- Acute hepatitis or known HIV.

- Active or uncontrolled infection.

- Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension,
unstable angina, and congestive heart failure.

- Prior therapy that affects or targets the EGF pathway.

- Prior allergic reaction to chimerized or murine monoclonal antibody therapy or
documented presence of human anti-mouse antibodies (HAMA).

- Any concurrent chemotherapy not indicated in the study protocol or any other
investigational agent(s).